Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16782899
Chen SY, Chen HC (2006) Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol 26, 5155-67 16782899
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y397-p - FAK (human)
Modsite: sVsEtDDyAEIIDEE SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y397‑p, FAK iso2 (human): Y216‑p, FAK iso5 (human): Y397‑p, FAK (mouse): Y397‑p, FAK iso2 (mouse): Y428‑p, FAK iso4 (mouse): Y397‑p, FAK iso9 (mouse): , FAK (rat): Y397‑p, FAK (chicken): Y397‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Met (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Met (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Src (human) increase v-src
Met (human) increase Tpr-Met
Met (human) inhibit treatment-induced increase Tpr-Met Y482F Y489F (equivalent to Y1349,Y1356)

Y407-p - FAK (human)
Modsite: IIDEEDtytMPSTRD SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y407‑p, FAK iso2 (human): Y226‑p, FAK iso5 (human): Y407‑p, FAK (mouse): Y407‑p, FAK iso2 (mouse): Y438‑p, FAK iso4 (mouse): Y407‑p, FAK iso9 (mouse): , FAK (rat): Y407‑p, FAK (chicken): Y407‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Met (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Met (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Src (human) increase v-src
Met (human) increase Tpr-Met
Met (human) inhibit treatment-induced increase Tpr-Met Y482F Y489F (equivalent to Y1349,Y1356)

Y576-p - FAK (human)
Modsite: RyMEDstyyKAsKGK SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y576‑p, FAK iso2 (human): Y424‑p, FAK iso5 (human): Y576‑p, FAK (mouse): Y576‑p, FAK iso2 (mouse): Y607‑p, FAK iso4 (mouse): Y576‑p, FAK iso9 (mouse): , FAK (rat): Y576‑p, FAK (chicken): Y576‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Met (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Met (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Src (human) increase v-src
Met (human) increase Tpr-Met
Met (human) inhibit treatment-induced increase Tpr-Met Y482F Y489F (equivalent to Y1349,Y1356)

Y577-p - FAK (human)
Modsite: yMEDstyyKAsKGKL SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y577‑p, FAK iso2 (human): Y425‑p, FAK iso5 (human): Y577‑p, FAK (mouse): Y577‑p, FAK iso2 (mouse): Y608‑p, FAK iso4 (mouse): Y577‑p, FAK iso9 (mouse): , FAK (rat): Y577‑p, FAK (chicken): Y577‑p, FAK iso5 (chicken):
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Met (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Met (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Src (human) increase v-src
Met (human) increase Tpr-Met
Met (human) inhibit treatment-induced increase Tpr-Met Y482F Y489F (equivalent to Y1349,Y1356)

Y861-p - FAK (human)
Modsite: PIGNQHIyQPVGKPD SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y861‑p, FAK iso2 (human): Y688‑p, FAK iso5 (human): Y861‑p, FAK (mouse): Y861‑p, FAK iso2 (mouse): Y892‑p, FAK iso4 (mouse): Y861‑p, FAK iso9 (mouse): Y169‑p, FAK (rat): Y861‑p, FAK (chicken): Y863‑p, FAK iso5 (chicken): Y169‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Met (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Met (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Src (human) increase v-src
Met (human) increase Tpr-Met
Met (human) inhibit treatment-induced increase Tpr-Met Y482F Y489F (equivalent to Y1349,Y1356)

Y925-p - FAK (human)
Modsite: DRsNDkVyENVtGLV SwissProt Entrez-Gene
Orthologous residues
FAK (human): Y925‑p, FAK iso2 (human): Y752‑p, FAK iso5 (human): Y938‑p, FAK (mouse): Y925‑p, FAK iso2 (mouse): Y956‑p, FAK iso4 (mouse): Y928‑p, FAK iso9 (mouse): Y233‑p, FAK (rat): Y928‑p, FAK (chicken): Y926‑p, FAK iso5 (chicken): Y232‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Met (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Met (human) co-immunoprecipitation, transfection of wild-type enzyme, pharmacological activator of upstream enzyme, transfection of constitutively active enzyme, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Src (human) increase v-src
Met (human) increase Tpr-Met
Met (human) inhibit treatment-induced increase Tpr-Met Y482F Y489F (equivalent to Y1349,Y1356)

Y1234-p - Met (human)
Modsite: RDMyDkEyysVHNkt SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1234‑p, Met iso2 (human): Y1252‑p, Met (mouse): Y1232‑p, Met (rat): Y1235‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase

Y1235-p - Met (human)
Modsite: DMyDkEyysVHNktG SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1235‑p, Met iso2 (human): Y1253‑p, Met (mouse): Y1233‑p, Met (rat): Y1236‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase

Y1349-p - Met (human)
Modsite: stFIGEHyVHVNAty SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1349‑p, Met iso2 (human): Y1367‑p, Met (mouse): Y1347‑p, Met (rat): Y1350‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Met (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
FAK (human) Induces enzymatic activity, induced pull-down assay, sequence-specific competitor, co-immunoprecipitation

Y1356-p - Met (human)
Modsite: yVHVNAtyVNVKCVA SwissProt Entrez-Gene
Orthologous residues
Met (human): Y1356‑p, Met iso2 (human): Y1374‑p, Met (mouse): Y1354‑p, Met (rat): Y1357‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), SYF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Met (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HGF increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
FAK (human) Induces enzymatic activity, induced pull-down assay, sequence-specific competitor, co-immunoprecipitation